HLA-G and cancer: Modulation of immune cell metabolism has been considered as an adjunct to immune CPI in patients with cancer.44 This suggests the need for further studies to explore whether the loss of HLA-G+ T cells’ inhibitory capacity through CTLA-4 blockade is accompanied by changes in cellular metabolites to determine possible metabolic targets in decompensated cirrhosis.